A longitudinal study on IL-2, sIL-2R, IL-4 and IFN-γ in multiple sclerosis CSF and serum

[1]  D. Clifford,et al.  Serial studies of serum interleukin-2 in chronic progressive multiple sclerosis patients: occurrence of ‘bursts’ and effect of cyclosporine , 1990, Journal of Neuroimmunology.

[2]  L. Pilarski,et al.  CD45R as a primary signal transducer stimulating IL-2 and IL-2R mRNA synthesis by CD3-4-8- thymocytes. , 1989, Journal of immunology.

[3]  M. Toribio,et al.  Differential Growth Requirements and Effector Functions of α/β and γ/δ Human T Cells , 1989, Immunological reviews.

[4]  T. Olsson,et al.  Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[5]  B. Giometto,et al.  Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and γ-IFN levels in serum and cerebrospinal fluid , 1989, Journal of the Neurological Sciences.

[6]  G. Kitas,et al.  Production of lymphokine mRNA by CD45R+ and CD45R- helper T cells from human peripheral blood and by human CD4+ T cell clones. , 1989, Journal of immunology.

[7]  G. Kroemer,et al.  The role of interleukin 2 in autoimmunity. , 1989, Immunology today.

[8]  T. Kindt,et al.  A susceptibility locus for multiple sclerosis is linked to the T cell receptor β chain complex , 1989, Cell.

[9]  S. Araki,et al.  INTERLEUKIN-2 RECEPTOR LEVELS INDICATING RELAPSE IN MULTIPLE SCLEROSIS , 1989, The Lancet.

[10]  H. Weiner,et al.  MS: a CNS and systemic autoimmune disease. , 1989, Immunology today.

[11]  M. Feldmann,et al.  MS: a localized immune disease of the central nervous system. , 1989, Immunology today.

[12]  L. Cavalli-Sforza,et al.  T-cell receptor V alpha and C alpha alleles associated with multiple and myasthenia gravis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Monica S. Perlmutter,et al.  Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis , 1989, Annals of neurology.

[14]  B. Tavolato,et al.  Interleukin‐2 levels in serum and cerebrospinal fluid of multiple sclerosis patients , 1988, Annals of neurology.

[15]  T. Waldmann,et al.  Elevated levels of soluble interleukin-2 receptors in multiple sclerosis. , 1988, The New England journal of medicine.

[16]  R. Fernandez-Botran,et al.  Lymphokine-mediated regulation of the proliferative response of clones of T helper 1 and T helper 2 cells , 1988, The Journal of experimental medicine.

[17]  D. Clifford,et al.  Elevated serum interleukin-2 levels in chronic progressive multiple sclerosis. , 1988, The New England journal of medicine.

[18]  S. Swain,et al.  The Role of IL4 and IL5: Characterization of a Distinct Helper T Cell Subset that makes IL4 and IL5 (Th2) and Requires Priming before Induction of Lymphokine Secretion , 1988, Immunological reviews.

[19]  H. Weiner,et al.  Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis. Analysis with anti-2H4 monoclonal antibody. , 1987, The New England journal of medicine.

[20]  E. Reinherz,et al.  In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. , 1985, The New England journal of medicine.

[21]  T. Olsson,et al.  Improved detection of oligoclonal IgG in cerebrospinal fluid by isoelectric focusing in agarose, double-antibody peroxidase labeling, and avidin-biotin amplification. , 1984, Clinical chemistry.

[22]  S. Ohman,et al.  Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. , 1977, Scandinavian journal of clinical and laboratory investigation.

[23]  G. Ellison,et al.  Criteria for the clinical diagnosis of multiple sclerosis , 1976, Neurology.

[24]  J. Kurtzke,et al.  Further notes on disability evaluation in multiple sclerosis, with scale modifications , 1965, Neurology.

[25]  F. Mcdowell,et al.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS , 1965, Annals of the New York Academy of Sciences.

[26]  K. Bottomly.  A functional dichotomy in CD4+ T lymphocytes. , 1988, Immunology today.

[27]  R. Coffman,et al.  Two types of mouse helper T-cell clone Implications for immune regulation. , 1987, Immunology today.